Trials / Completed
CompletedNCT02231450
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
Interventional, Open-label, Three-group Study to Determine the Pharmacokinetic Properties of Single Oral Dosing of Lu AE58054 in Patients With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of Lu AE58054 following a single oral dose of Lu AE58054
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AE58054 encapsulated film-coated tablets |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-03-01
- First posted
- 2014-09-04
- Last updated
- 2015-03-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02231450. Inclusion in this directory is not an endorsement.